In our study, CD82 inactivated p38 MAPK and downregulated expression of p16 in leukemia cells (Fig 4B–4D), suggesting that CD82 might inhibit senescence in CD34+/CD38− AML cells via inactivation of p38 MAPK signaling and suppression of p16 expression. The gene discussed is CD38; the disease is leukemia.